TY - JOUR T1 -一线卡铂加培美曲塞与培美曲塞维持治疗hiv阳性晚期非鳞非小细胞肺癌患者:二期ifct - 1001 CHIVA审判JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02066 -2019欧元六世- 56 - 2 SP - 1902066 AU Lavole Armelle盟——Greillier Laurent盟——Mazieres朱利安AU -莫内,伊莎贝尔盟——Kiakouama-Maleka Lize盟——Quantin Xavier AU -斯帕诺,让菲利普盟——丽娜,Herve盟——Fraisse Philippe AU - Janicot亨利AU - Audigier-Valette,她非盟- Langlais,亚历山德拉AU -莫林,弗兰克盟——梅金森阿兰盟——Cadranel雅克•A2 -Y1 - 2020/08/01 UR - //www.qdcxjkg.com/content/56/2/1902066.abstract N2 - HIV感染是肺癌试验的排除标准。这项多中心II期试验旨在评估一线卡铂联合培美曲塞(CaP)在晚期非鳞状非小细胞肺癌(NS-NSCLC)艾滋病毒感染者(PLHIV)中维持培美曲塞(P)的可行性、有效性和安全性。东部肿瘤合作组(Eastern Cooperative Oncology Group)表现状态≤2的患者接受4个周期CaP后p维持治疗。主要目标是12周后疾病控制率(DCR)≥30%。在纳入的61例PLHIV患者中，49例(80%)的表现状态为0-1,19例(31%)有脑转移。中位CD4淋巴细胞计数为418细胞·µL−1(18-1230)，中位CD4淋巴细胞最低点为169.5细胞·µL−1 (1 - 822);48例(80%)病毒学控制。38例(62%)患者实现了四个周期诱导，31例(51%)患者开始p维持(中位数4.1个周期(范围1-19))。12周DCR为50.8% (95% CI 38.3-63.4)，部分缓解率为21.3%。 Median progression-free survival and overall survival were 3.5 (95% CI 2.7–4.4) and 7.6 months (5.7–12.8), respectively. Patients with a performance status of 0–1 had the longest median progression-free survival (4.3 months, 95% CI 3.1–5.2) and overall survival (11.9 months, 95% CI 6.4–14.3). During induction, CaP doublet was well tolerated apart from grade 3–4 haematological toxicities (neutropenia 53.8%; thrombocytopenia 35.0%; anaemia 30.0%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced.In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.In this first clinical trial dedicated to people living with HIV and advanced non-squamous non-small cell lung cancer, first-line 4-cycle carboplatin plus pemetrexed followed by pemetrexed maintenance chemotherapy was effective and reasonably well-tolerated https://bit.ly/2xAqeEl ER -